| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| ln Vitro |
CIM-834 (0-10 μM; 3-5 d) can effectively inhibit the replication of SARS-CoV and HCoV-OC43, and has partial activity against HCoV-229E, but has no activity against HCoV-NL63, FIPV, PEDV and MERS-CoV[1].
|
|---|---|
| ln Vivo |
CIM-834 (100 mg/kg; orally; once or twice daily for 3 consecutive days) reduced the SARS-CoV-2 infection titer in the lungs of SCID mice [1]. CIM-834 (100 mg/kg, orally, twice daily for 4 consecutive days, in combination with ritonavir 50 mg/kg, orally, twice daily) reduced the SARS-CoV-2 titer in the lungs of Syrian hamsters [1].
|
| Animal Protocol |
Animal/Disease Models:CB-17/Icr-Prkdcscid/scid/Rj SCID mice (male, 7-9 weeks old, intranasally infected with SARS-CoV-2 B.1.351) [1]
Doses: 100 mg/kg (once daily; twice daily) Route of Administration: Oral; once daily for 3 consecutive days; oral; twice daily for 3 consecutive days Experimental Results: Significantly and dose-dependently reduced the infectious virus titer and viral RNA load in lung tissue. Administration within 48 hours of infection reduced the infectious virus titer in the lungs of mice by more than 3 log₁₀. Animal/Disease Models:Syrian hamsters (female, 8–10 weeks old, intranasally infected with SARS-CoV-2 USA-WA1/2020)[1] Doses: 100 mg/kg (CIM-834); 50 mg/kg (ritonavir) Route of Administration: Oral; twice daily; 4 days (CIM-834 and ritonavir combined) Experimental Results: Lung viral RNA levels decreased by 3.4 log10, and infectious viral titers decreased by more than 4 log10. Lung parenchyma almost returned to normal, with only focal perivascular inflammation. SARS-CoV-2 transmission from treated indicator hamsters to untreated sentinel hamsters was prevented. |
| References |
| Molecular Formula |
C27H42N8O
|
|---|---|
| Molecular Weight |
494.68
|
| CAS # |
3104363-32-5
|
| Appearance |
White to off-white solid
|
| SMILES |
CC1=NC(N2CCC(N(C)C3=CC(C(NCCN4CCCC4)=O)=CN=N3)CC2)=NC(C)=C1CC(C)C
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~202.15 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.05 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.05 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.05 mM)(saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0215 mL | 10.1075 mL | 20.2151 mL | |
| 5 mM | 0.4043 mL | 2.0215 mL | 4.0430 mL | |
| 10 mM | 0.2022 mL | 1.0108 mL | 2.0215 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
